Drug Interaction Report
1 drug interaction and 18 additional warnings found for the following 2 drugs:
- tepotinib
- Vafseo (vadadustat)
Drug interactions
Moderate drug interactions
Moderate:tepotinib vadadustat
Applies to: tepotinib, Vafseo (vadadustat)
Vadadustat may increase the blood levels and effects of tepotinib.
You may need more frequent monitoring by your doctor to safely use both medications. Contact your doctor if your condition changes or you experience increased side effects.
It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.
Food/lifestyle interactions
Moderate food/lifestyle interactions
Moderate:Food/Lifestyle tepotinib
Applies to: tepotinib
Food helps with the absorption of tepotinib into the blood stream.
You should take this medication with food at approximately the same time each day.
Moderate:Food/Lifestyle vadadustat
Applies to: Vafseo (vadadustat)
Using vadadustat while smoking or drinking alcohol may increase the risk of side effects in the gastrointestinal tract such as stomach inflammation and bleeding.
Talk to your doctor if you have any questions or concerns.
You should seek immediate medical attention if you have signs and symptoms of gastrointestinal bleeding such as:
- abdominal pain
- coughing up or vomiting fresh or dried blood that looks like coffee grounds
- black, tarry stools
- trouble swallowing
- chest or throat pain
It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.
Disease interactions
16 potential interactionsApplies to: 15 conditions, including High Blood Pressure, Seizures, Breast Cancer, Prostate Cancer, and Liver Disease.
Alcoholism
Moderate:Vafseo
The vadadustat in Vafseo has a moderate potential interaction with Alcoholism.
Esophageal and gastrointestinal erosions have been reported with the use of vadadustat. Some cases of serious gastrointestinal bleeding required the need for red blood cell transfusions. Patients with history of gastrointestinal erosion, peptic ulcer disease, tobacco smokers and alcohol drinkers are at increased risk.
Bladder Cancer
Moderate:Vafseo
The vadadustat in Vafseo has a moderate potential interaction with Bladder Cancer.
An increase in hypoxia inducible factor (HIF) levels may be associated with unfavorable effects on cancer growth. The use of vadadustat has not been studied and is not recommended in patients with active malignancies.
Breast Cancer
Moderate:Vafseo
The vadadustat in Vafseo has a moderate potential interaction with Breast Cancer.
An increase in hypoxia inducible factor (HIF) levels may be associated with unfavorable effects on cancer growth. The use of vadadustat has not been studied and is not recommended in patients with active malignancies.
Cardiovascular Conditions and Disorders
Moderate:Vafseo
The vadadustat in Vafseo has a moderate potential interaction with Cardiovascular Conditions and Disorders.
Vadadustat increases the risk of arterial and venous thrombotic events, including major adverse cardiovascular events. Patients with cardiovascular or cerebrovascular disease are at increased risk. Avoid the use of this drug in patients with history of myocardial infarction, cerebrovascular events, or acute coronary syndrome within the 3 months prior to starting treatment.
Esophageal Disease
Moderate:Vafseo
The vadadustat in Vafseo has a moderate potential interaction with Esophageal Disease.
Esophageal and gastrointestinal erosions have been reported with the use of vadadustat. Some cases of serious gastrointestinal bleeding required the need for red blood cell transfusions. Patients with history of gastrointestinal erosion, peptic ulcer disease, tobacco smokers and alcohol drinkers are at increased risk.
Gastrointestinal Hemorrhage
Moderate:Vafseo
The vadadustat in Vafseo has a moderate potential interaction with Gastrointestinal Hemorrhage.
Esophageal and gastrointestinal erosions have been reported with the use of vadadustat. Some cases of serious gastrointestinal bleeding required the need for red blood cell transfusions. Patients with history of gastrointestinal erosion, peptic ulcer disease, tobacco smokers and alcohol drinkers are at increased risk.
High Blood Pressure
Major:Vafseo
The vadadustat in Vafseo has a major potential interaction with High Blood Pressure.
Vadadustat is contraindicated in patients with uncontrolled hypertension as cases of hypertensive crisis including hypertensive encephalopathy and seizures have been reported. Patients with history of seizure disorders receiving this drug should be monitored closely and should contact their health care provider for premonitory symptoms or change in seizure frequency.
Liver Disease
Moderate:tepotinib
Tepotinib has a moderate potential interaction with Liver Disease.
The use of tepotinib may cause hepatotoxicity, sometimes resulting in fatalities. No dosage modification is recommended in patients with mild (Child-Pugh A) or moderate (Child-Pugh B) liver dysfunction. Care should be exercised when using tepotinib in patients with severe liver dysfunction (Child-Pugh C) as its pharmacokinetics and safety have not been studied in this patient population. It is recommended to monitor liver function tests (including ALT, AST, and total bilirubin) prior to the start of therapy, every 2 weeks during the first 3 months of therapy, then once a month or as clinically indicated, with more frequent testing in patients who develop increased transaminases or bilirubin. Tepotinib should be withheld, the dose should be reduced, or therapy should be permanently discontinued based on the severity of the adverse reaction.
Moderate:Vafseo
The vadadustat in Vafseo has a moderate potential interaction with Liver Disease.
Vadadustat may cause hepatotoxicity. Liver enzymes and bilirubin should be measured prior to treatment initiation and monitored during treatment. This drug is not recommended in patients with cirrhosis, or active, acute liver disease.
Lung Cancer
Moderate:Vafseo
The vadadustat in Vafseo has a moderate potential interaction with Lung Cancer.
An increase in hypoxia inducible factor (HIF) levels may be associated with unfavorable effects on cancer growth. The use of vadadustat has not been studied and is not recommended in patients with active malignancies.
Prostate Cancer
Moderate:Vafseo
The vadadustat in Vafseo has a moderate potential interaction with Prostate Cancer.
An increase in hypoxia inducible factor (HIF) levels may be associated with unfavorable effects on cancer growth. The use of vadadustat has not been studied and is not recommended in patients with active malignancies.
Pulmonary Impairment
Moderate:tepotinib
Tepotinib has a moderate potential interaction with Pulmonary Impairment.
The use of tepotinib may cause interstitial lung disease (ILD)/pneumonitis, sometimes resulting in fatalities. Care should be exercised when using this drug in patients with preexisting pulmonary impairment. Tepotinib should be immediately withheld in patients with suspected ILD/pneumonitis and permanently discontinued if no other potential causes of ILD/pneumonitis are identified. Patients should be monitored for new/worsening pulmonary symptoms indicative of ILD/pneumonitis.
Renal Dysfunction
Moderate:tepotinib
Tepotinib has a moderate potential interaction with Renal Dysfunction.
Care should be exercised when using tepotinib in patients with severe renal dysfunction (CrCl less than 30 mL/min) as the recommended dosage has not been established in this patient population. No dosage adjustment is recommended in patients with mild or moderate renal dysfunction (CrCl 30 to 89 mL/min).
Seizures
Major:Vafseo
The vadadustat in Vafseo has a major potential interaction with Seizures.
Vadadustat is contraindicated in patients with uncontrolled hypertension as cases of hypertensive crisis including hypertensive encephalopathy and seizures have been reported. Patients with history of seizure disorders receiving this drug should be monitored closely and should contact their health care provider for premonitory symptoms or change in seizure frequency.
Skin Cancer
Moderate:Vafseo
The vadadustat in Vafseo has a moderate potential interaction with Skin Cancer.
An increase in hypoxia inducible factor (HIF) levels may be associated with unfavorable effects on cancer growth. The use of vadadustat has not been studied and is not recommended in patients with active malignancies.
Smoking
Moderate:Vafseo
The vadadustat in Vafseo has a moderate potential interaction with Smoking.
Esophageal and gastrointestinal erosions have been reported with the use of vadadustat. Some cases of serious gastrointestinal bleeding required the need for red blood cell transfusions. Patients with history of gastrointestinal erosion, peptic ulcer disease, tobacco smokers and alcohol drinkers are at increased risk.
Report options
- Switch to professional interaction data
- Email this report to a friend, doctor, or patient
- Ask questions, find answers
Drug Interaction Classification
| Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
| Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
| Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
| No interaction information available. |
See also:
Learn more
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.